Prostate adenocarcinoma grade group 1: Rationale for retaining a cancer label in the 2022 World Health Organization classification
Authors listGeorge J Netto Mahul B Amin Eva M Compérat Anthony J Gill Arndt Hartmann Holger Moch Santosh Menon Maria R Raspollini Mark A Rubin John R Srigley Puay Hoon Tan Satish K Tickoo Toyonori Tsuzuki Samra Turajlic Ian Cree Daniel M Berney
We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.
Journal European Urology
Issue number 4